Advanced Search

 

Study ID Status Title Patient Level Data
NKE20001 Completed A Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Parallel Group Study of the Efficacy and Safety of a New Chemical Entity When Administered as Oral Tablets in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induc ...
NKF100096 Completed A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major depressive Disorder (MDD) Study Listed on ClinicalStudyDataRequest.com
NKF100110 Completed A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Social Anxiety Disorder Study Listed on ClinicalStudyDataRequest.com
NKG10004 Completed A Parallel Group, Single-Blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GW823296 and its Effect on the Pharmacokinetics of Midazolam after Once-Daily Repeated Oral Doses in Healthy Subjects
NKG10006 Completed A Randomized, Double-Blind, Placebo-Controlled, Three Armed fMRI study Comparing Emotion-Induced Brain Activation Patterns Before and After 8 Weeks of Treatment With Placebo, Active Comparator (PAXIL, 20 mg), and a GSK New Chemical Entity (NCE) Study Listed on ClinicalStudyDataRequest.com
NKI110334 Completed A multi-centre, randomized, double-blind, placebo-controlled, cross-over study to evaluate the effects of GW597599 and GR205171 on sleep continuity, PSG sleep recordings, subjective sleep assessment and daytime cognitive function in subjects with primary insomnia Study Listed on ClinicalStudyDataRequest.com
NKO101287 Completed Phase II Multicenter, Dose Ranging Study on the Safety and Antiemetic Efficacy of One Day Intraveous dosing of GW597599 administered with Ondansetron HCL in a female subjects undergoing surgical procedures of high emetogenic risk
NKP102280 Completed A double-blind, triple dummy, placebo-controlled, randomised, parallel group positron emission tomography study to investigate the effects of a 8 week administration of GW597599 and paroxetine either alone or in combination on regional cerebral blood flow during a public speaking test in subjects affected by social phobia. Study Listed on ClinicalStudyDataRequest.com
NKP103401 Completed A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/paroxetine combination or paroxetine monotherapy to placebo in Patients with Social Anxiety Disorder (SAD) Study Listed on ClinicalStudyDataRequest.com
NKP106254 Completed Randomised, double-blind, placebo controlled, cross-over study comparing the effects of both single dose and repeated dosing treatment for 14 days of vestipitant or vestipitant / paroxetine combination in an enriched population of subjects with tinnitus & hearing loss Study Listed on ClinicalStudyDataRequest.com
NKT102245 Completed See Detailed Description
NKT102260 Completed See Detailed Description
NKT102552 Completed A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis Study Listed on ClinicalStudyDataRequest.com
NKT102553 Completed A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50mg Oral Dosing with the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis Study Listed on ClinicalStudyDataRequest.com
NKT102783 Completed An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects with Renal Impairment Study Listed on ClinicalStudyDataRequest.com
NKT102785 Completed An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in subjects with Hepatic Impairment Study Listed on ClinicalStudyDataRequest.com
NKV10001 Completed An open label, repeat dose, randomized, three period crossover, parallel group study to investigate the potential pharmacokinetic interactions between two doses of a new chemical entity (NCE) and ondansetron (OND) and dexamethasone (DEX) when co-administered in healthy adult subjects.
NKV100781 Completed A Phase I, Open-Label, Randomized, Two Period Crossover Study to Investigate the Effects of GW679769 on the Pharmacokinetics of Docetaxel in Subjects with Cancer Study Listed on ClinicalStudyDataRequest.com
NKV100787 Completed An Open-Label, Phase I Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant [GW679769] and Intravenous and Oral Doses of Dexamethasone and Intravenous and Oral Doses of Ondansetron when Administered in Healthy Adult Subjects
NKV101983 Completed A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study of the Safety and Efficacy of the Oral NeuroKinin-1 Receptor Antagonist, GW679769 in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea
NKV102549 Completed A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist Casopitant (GW679769) in Combination with Ondansetron and Dexamethasone for the Prevention of Nausea
NKV102551 Completed A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant, administered in Combination with ZOFRAN and Dexamethasone for Prevention of Chemotherapy
NKV103444 Terminated An open label, repeat dose, randomized, two period crossover study to investigate the potential pharmacokinetic interactions between oral GW679769 and intravenous cyclophosphamide in cancer patients
NKV105091 Completed An Open-Label, Two Period, Fixed Sequence Study of Healthy Subjects to Assess the Effect of Repeat Oral Dosing of [Rifampin] on the Pharmacokinetics of a Single Oral Dose of [GW679769] Study Listed on ClinicalStudyDataRequest.com
NKV105093 Completed An open-label, two period, fixed sequence study of healthy subjects to assess the effect of repeat oral dosing of ketoconazole on the pharmacokinetics of a single oral dose of [GW679769] Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.